BACKGROUND: World Health Organization guidelines for antiretroviral treatment (ART) in resource-limited settings recommend either stavudine or tenofovir as part of initial therapy. We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine. METHODS: We used a state-transition model of human immunodeficiency virus (HIV) disease to examine strategies using different nucleoside reverse-transcriptase inhibitors, combined with lamivudine and nevirapine, compared with no ART: (1) stavudine, (2) stavudine with substitution by zidovudine after 6 months, (3) zidovudine, and (4) tenofovir. Data were from the Y. R. Gaitonde Centre for AIDS Research and Education in Chennai, India, and published studies. Results. Discounted mean per person survival was 36.9 months (40.2 months undiscounted) with no ART, 115.5 months (145.3) with stavudine-containing ART, 115.7 months (145.6) with stavudine and 6-month zidovudine substitution, 115.8 months (145.6) with zidovudine-containing ART, and 125.8 months (162.0) with initial tenofovir. Discounted lifetime medical costs were $610 with no ART and ranged from $5580 with stavudine-containing ART to $5720 with zidovudine-containing ART. Initial tenofovir had an incremental cost-effectiveness ratio of $670 per year of life saved, compared with no ART, and was more economically efficient than the other regimens. RESULTS: were most sensitive to variations in the costs of first-line tenofovir, access to additional ART after treatment failure, and quality of life adjustment. CONCLUSIONS: Using tenofovir as part of first-line ART in India will improve survival, is cost-effective by international standards, and should be considered for initial therapy for HIV-infected patients in India.
BACKGROUND: World Health Organization guidelines for antiretroviral treatment (ART) in resource-limited settings recommend either stavudine or tenofovir as part of initial therapy. We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine. METHODS: We used a state-transition model of humanimmunodeficiency virus (HIV) disease to examine strategies using different nucleoside reverse-transcriptase inhibitors, combined with lamivudine and nevirapine, compared with no ART: (1) stavudine, (2) stavudine with substitution by zidovudine after 6 months, (3) zidovudine, and (4) tenofovir. Data were from the Y. R. Gaitonde Centre for AIDS Research and Education in Chennai, India, and published studies. Results. Discounted mean per person survival was 36.9 months (40.2 months undiscounted) with no ART, 115.5 months (145.3) with stavudine-containing ART, 115.7 months (145.6) with stavudine and 6-month zidovudine substitution, 115.8 months (145.6) with zidovudine-containing ART, and 125.8 months (162.0) with initial tenofovir. Discounted lifetime medical costs were $610 with no ART and ranged from $5580 with stavudine-containing ARTto $5720 with zidovudine-containing ART. Initial tenofovir had an incremental cost-effectiveness ratio of $670 per year of life saved, compared with no ART, and was more economically efficient than the other regimens. RESULTS: were most sensitive to variations in the costs of first-line tenofovir, access to additional ART after treatment failure, and quality of life adjustment. CONCLUSIONS: Using tenofovir as part of first-line ART in India will improve survival, is cost-effective by international standards, and should be considered for initial therapy for HIV-infectedpatients in India.
Authors: Patrick Marcellin; E Jenny Heathcote; Maria Buti; Ed Gane; Robert A de Man; Zahary Krastev; George Germanidis; Sam S Lee; Robert Flisiak; Kelly Kaita; Michael Manns; Iskren Kotzev; Konstantin Tchernev; Peter Buggisch; Frank Weilert; Oya Ovung Kurdas; Mitchell L Shiffman; Huy Trinh; Mary Kay Washington; Jeff Sorbel; Jane Anderson; Andrea Snow-Lampart; Elsa Mondou; Joe Quinn; Franck Rousseau Journal: N Engl J Med Date: 2008-12-04 Impact factor: 91.245
Authors: Bruce R Schackman; Callie A Scott; Rochelle P Walensky; Elena Losina; Kenneth A Freedberg; Paul E Sax Journal: AIDS Date: 2008-10-01 Impact factor: 4.177
Authors: N Kumarasamy; Kartik K Venkatesh; Anitha J Cecelia; Bella Devaleenal; Andrew R Lai; Suneeta Saghayam; P Balakrishnan; Toku Yepthomi; S Poongulali; Timothy P Flanigan; Suniti Solomon; Kenneth H Mayer Journal: AIDS Patient Care STDS Date: 2008-04 Impact factor: 5.078
Authors: Andrew Reid; Wolfgang Stöhr; A Sarah Walker; Ian G Williams; Cissy Kityo; Peter Hughes; Andrew Kambugu; Charles F Gilks; Peter Mugyenyi; Paula Munderi; James Hakim; Diana M Gibb Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079
Authors: Sharon A Riddler; Richard Haubrich; A Gregory DiRienzo; Lynne Peeples; William G Powderly; Karin L Klingman; Kevin W Garren; Tania George; James F Rooney; Barbara Brizz; Umesh G Lalloo; Robert L Murphy; Susan Swindells; Diane Havlir; John W Mellors Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240